151 related articles for article (PubMed ID: 37933642)
81. An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity.
Xu Y; Carrascosa LC; Yeung YA; Chu ML; Yang W; Djuretic I; Pappas DC; Zeytounian J; Ge Z; de Ruiter V; Starbeck-Miller GR; Patterson J; Rigas D; Chen SH; Kraynov E; Boor PP; Noordam L; Doukas M; Tsao D; Ijzermans JN; Guo J; Grünhagen DJ; Erdmann J; Verheij J; van Royen ME; Doornebosch PG; Feldman R; Park T; Mahmoudi S; Dorywalska M; Ni I; Chin SM; Mistry T; Mosyak L; Lin L; Ching KA; Lindquist KC; Ji C; Londono LM; Kuang B; Rickert R; Kwekkeboom J; Sprengers D; Huang TH; Chaparro-Riggers J
Cancer Immunol Res; 2021 Oct; 9(10):1141-1157. PubMed ID: 34376502
[TBL] [Abstract][Full Text] [Related]
82. ABIN-1 is a key regulator in RIPK1-dependent apoptosis (RDA) and necroptosis, and ABIN-1 deficiency potentiates necroptosis-based cancer therapy in colorectal cancer.
Cai J; Hu D; Sakya J; Sun T; Wang D; Wang L; Mao X; Su Z
Cell Death Dis; 2021 Feb; 12(2):140. PubMed ID: 33542218
[TBL] [Abstract][Full Text] [Related]
83. PITPNC1 Suppress CD8
Liang J; Liao L; Xie L; Tang W; Yu X; Lu Y; Chen H; Xu J; Sun L; Wu H; Cui C; Tan Y
J Transl Med; 2024 Jan; 22(1):117. PubMed ID: 38291470
[TBL] [Abstract][Full Text] [Related]
84. The Prognostic Significance of the Tumor-infiltrating Programmed Cell Death-1
Shibutani M; Maeda K; Nagahara H; Fukuoka T; Nakao S; Matsutani S; Hirakawa K; Ohira M
Anticancer Res; 2017 Aug; 37(8):4165-4172. PubMed ID: 28739701
[TBL] [Abstract][Full Text] [Related]
85. Inverse relationship between CD40L expression and cytolytic molecule expression by CD8
Xing J; Li X; E J; Wang C; Wang H
Exp Cell Res; 2020 Apr; 389(1):111892. PubMed ID: 32035135
[TBL] [Abstract][Full Text] [Related]
86. The inhibitory receptor CD94/NKG2A on CD8
Eugène J; Jouand N; Ducoin K; Dansette D; Oger R; Deleine C; Leveque E; Meurette G; Podevin J; Matysiak T; Bennouna J; Bezieau S; Volteau C; Thomas WEA; Chetritt J; Kerdraon O; Fourquier P; Thibaudeau E; Dumont F; Mosnier JF; Toquet C; Jarry A; Gervois N; Bossard C
Mod Pathol; 2020 Mar; 33(3):468-482. PubMed ID: 31409873
[TBL] [Abstract][Full Text] [Related]
87. Intratumoral infiltrating lymphocytes correlate with improved survival in colorectal cancer patients: Independent of oncogenetic features.
Nazemalhosseini-Mojarad E; Mohammadpour S; Torshizi Esafahani A; Gharib E; Larki P; Moradi A; Amin Porhoseingholi M; Asadzade Aghdaei H; Kuppen PJK; Zali MR
J Cell Physiol; 2019 Apr; 234(4):4768-4777. PubMed ID: 30370522
[TBL] [Abstract][Full Text] [Related]
88. Identification of an at-risk subpopulation with high immune infiltration based on the peroxisome pathway and TIM3 in colorectal cancer.
Yin J; Wang H; Hong Y; Ren A; Wang H; Liu L; Zhao Q
BMC Cancer; 2022 Jan; 22(1):44. PubMed ID: 34996408
[TBL] [Abstract][Full Text] [Related]
89. Translocator protein-targeted photodynamic therapy for direct and abscopal immunogenic cell death in colorectal cancer.
Xie Q; Li Z; Liu Y; Zhang D; Su M; Niitsu H; Lu Y; Coffey RJ; Bai M
Acta Biomater; 2021 Oct; 134():716-729. PubMed ID: 34329783
[TBL] [Abstract][Full Text] [Related]
90. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer.
Zalba S; Contreras AM; Haeri A; Ten Hagen TL; Navarro I; Koning G; Garrido MJ
J Control Release; 2015 Jul; 210():26-38. PubMed ID: 25998052
[TBL] [Abstract][Full Text] [Related]
91. Galectin-1 fosters an immunosuppressive microenvironment in colorectal cancer by reprogramming CD8
Cagnoni AJ; Giribaldi ML; Blidner AG; Cutine AM; Gatto SG; Morales RM; Salatino M; Abba MC; Croci DO; Mariño KV; Rabinovich GA
Proc Natl Acad Sci U S A; 2021 May; 118(21):. PubMed ID: 34006646
[TBL] [Abstract][Full Text] [Related]
92. Celastrol upregulated ATG7 triggers autophagy via targeting Nur77 in colorectal cancer.
Zhang W; Wu Z; Qi H; Chen L; Wang T; Mao X; Shi H; Chen H; Zhong M; Shi X; Wang X; Li Q
Phytomedicine; 2022 Sep; 104():154280. PubMed ID: 35752079
[TBL] [Abstract][Full Text] [Related]
93. IL18 Receptor Signaling Regulates Tumor-Reactive CD8+ T-cell Exhaustion via Activation of the IL2/STAT5/mTOR Pathway in a Pancreatic Cancer Model.
Lutz V; Hellmund VM; Picard FSR; Raifer H; Ruckenbrod T; Klein M; Bopp T; Savai R; Duewell P; Keber CU; Weigert A; Chung HR; Buchholz M; Menke A; Gress TM; Huber M; Bauer C
Cancer Immunol Res; 2023 Apr; 11(4):421-434. PubMed ID: 36758176
[TBL] [Abstract][Full Text] [Related]
94. Immune Checkpoint Inhibitor-induced Reinvigoration of Tumor-infiltrating CD8
Park J; Kwon M; Kim KH; Kim TS; Hong SH; Kim CG; Kang SG; Moon JH; Kim EH; Park SH; Chang JH; Shin EC
Clin Cancer Res; 2019 Apr; 25(8):2549-2559. PubMed ID: 30659023
[TBL] [Abstract][Full Text] [Related]
95. Hitchhiking nanoparticles: Reversible coupling of lipid-based nanoparticles to cytotoxic T lymphocytes.
Wayteck L; Dewitte H; De Backer L; Breckpot K; Demeester J; De Smedt SC; Raemdonck K
Biomaterials; 2016 Jan; 77():243-54. PubMed ID: 26606450
[TBL] [Abstract][Full Text] [Related]
96. Targeting m
Bao Y; Zhai J; Chen H; Wong CC; Liang C; Ding Y; Huang D; Gou H; Chen D; Pan Y; Kang W; To KF; Yu J
Gut; 2023 Aug; 72(8):1497-1509. PubMed ID: 36717220
[TBL] [Abstract][Full Text] [Related]
97. Astragalus polysaccharide ameliorates CD8
Li Q; Zhang C; Xu G; Shang X; Nan X; Li Y; Liu J; Hong Y; Wang Q; Peng G
Biomed Pharmacother; 2024 Feb; 171():116172. PubMed ID: 38278025
[TBL] [Abstract][Full Text] [Related]
98. SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate.
Wong CC; Qian Y; Li X; Xu J; Kang W; Tong JH; To KF; Jin Y; Li W; Chen H; Go MY; Wu JL; Cheng KW; Ng SS; Sung JJ; Cai Z; Yu J
Gastroenterology; 2016 Nov; 151(5):945-960.e6. PubMed ID: 27451147
[TBL] [Abstract][Full Text] [Related]
99. Microenvironmental ammonia enhances T cell exhaustion in colorectal cancer.
Bell HN; Huber AK; Singhal R; Korimerla N; Rebernick RJ; Kumar R; El-Derany MO; Sajjakulnukit P; Das NK; Kerk SA; Solanki S; James JG; Kim D; Zhang L; Chen B; Mehra R; Frankel TL; Győrffy B; Fearon ER; Pasca di Magliano M; Gonzalez FJ; Banerjee R; Wahl DR; Lyssiotis CA; Green M; Shah YM
Cell Metab; 2023 Jan; 35(1):134-149.e6. PubMed ID: 36528023
[TBL] [Abstract][Full Text] [Related]
100. FePd Nanozyme- and SKN-Encapsulated Functional Lipid Nanoparticles for Cancer Nanotherapy via ROS-Boosting Necroptosis.
Xie W; Li Y; Guo Z; Lu J; Li G; Zhang Z; Zhang F; Wei Y; Wang X; Zhao L
ACS Appl Mater Interfaces; 2024 Apr; 16(15):18411-18421. PubMed ID: 38584383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
